{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:10:13Z","timestamp":1786119013813,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>There is little evidence about linezolid-attributed toxicity in children with drug-resistant tuberculosis. In a prospective cohort of South African children treated with linezolid, anemia, thrombocytopenia and peripheral neuropathy were common, sometimes severe, and often required active management. Peripheral neuropathy and grade 3\/4 events typically occurred after \u22653 months of treatment.<\/jats:p>","DOI":"10.1097\/inf.0000000000005135","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:00:29Z","timestamp":1767589229000},"page":"495-497","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Linezolid Toxicity in South African Children With Rifampicin-resistant Tuberculosis"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7965-5728","authenticated-orcid":false,"given":"Sacha","family":"Horn","sequence":"first","affiliation":[{"name":"Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louvina E.","family":"van der Laan","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik Simon","family":"Schaaf","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke C.","family":"Hesseling","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Garcia-Prats","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin"},{"name":"Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"R1-20260508","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5588\/ijtld.17.0357","article-title":"The burden of multidrug-resistant tuberculosis in children.","volume":"22","author":"Jenkins","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"R2-20260508","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis.","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"R3-20260508","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5588\/ijtld.11.0451","article-title":"Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"16","author":"Cox","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"R4-20260508","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"key":"R6-20260508","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis.","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"R7-20260508","doi-asserted-by":"crossref","first-page":"e1002789","DOI":"10.1371\/journal.pmed.1002789","article-title":"Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational studies.","volume":"16","author":"Garcia-Prats","year":"2019","journal-title":"PLoS Med"},{"key":"R8-20260508","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/cid\/ciab641","article-title":"Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children.","volume":"74","author":"Radtke","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R13-20260508","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(25)00213-0","article-title":"Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.","volume":"25","author":"Heinrich","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"R14-20260508","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1473-3099(25)00289-0","article-title":"Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.","volume":"25","author":"Minja","year":"2025","journal-title":"Lancet Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:33:39Z","timestamp":1786037619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005135","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}